Ilaria Grazia Zizzari

List of Publications by Year
in descending order

32 papers	**1,160** citations	430874 **18** h-index	434195 **31** g-index
33 all docs	**33** docs citations	**33** times ranked	**2072** citing authors

#	Article	IF	Citations
1	CAR-T cells: the long and winding road to solid tumors. Cell Death and Disease, 2018, 9, 282.	6.3	312
2	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. Journal of Translational Medicine, 2020, 18, 49.	4.4	114
3	Targeting of macrophage galactose–type <scp>C</scp>–type lectin (<scp>MGL</scp>) induces <scp>DC</scp> signaling and activation. European Journal of Immunology, 2012, 42, 936-945.	2.9	84
4	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. Journal of Translational Medicine, 2019, 17, 99.	4.4	52
5	MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	49
6	TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway. Cancer Immunology Research, 2018, 6, 711-722.	3.4	47
7	Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 705096.	4.8	47
8	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers, 2019, 11, 1055.	3.7	40
9	The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoS ONE, 2015, 10, e0132617.	2.5	35
10	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Frontiers in Immunology, 2020, 11, 1243.	4.8	30
11	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	3.3	28
12	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. Journal of Personalized Medicine, 2021, 11, 651.	2.5	28
13	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine, 2019, 8, 380.	2.4	25
14	Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing. Cancer Immunology Research, 2014, 2, 177-186.	3.4	23
15	Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells. Frontiers in Immunology, 2018, 9, 2481.	4.8	23
16	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. Journal of Personalized Medicine, 2020, 10, 208.	2.5	23
17	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2⁻ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. EBioMedicine, 2022, 79, 104010.	6.1	22
18	Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells. Frontiers in Immunology, 2017, 8, 1179.	4.8	21

#	Article	IF	Citations
19	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2018, 150, 151-157.	1.4	21
20	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 2620.	3.7	21
21	Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma. Journal of Personalized Medicine, 2020, 10, 112.	2.5	20
22	Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. Frontiers in Oncology, 2021, 11, 755433.	2.8	15
23	HER2-based recombinant immunogen to target DCs through FcÎ³Rs for cancer immunotherapy. Journal of Molecular Medicine, 2011, 89, 1231-1240.	3.9	12
24	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. Anticancer Research, 2016, 36, 5109-5116.	1.1	11
25	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). Cancers, 2020, 12, 2841.	3.7	10
26	IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. EBioMedicine, 2020, 62, 103098.	6.1	10
27	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. Clinical Cancer Research, 2022, 28, 1027-1037.	7.0	10
28	Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Human Immunology, 2016, 77, 1239-1247.	2.4	8
29	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ¯ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	8
30	Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 6312.	4.1	6
31	Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	3.3	5
32	Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. BioMed Research International, 2018, 2018, 1-2.	1.9	0